SCHEMBL468298

SCHEMBL468298

CC(=O)N(CC(=O)O)c1c[nH]c2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.52
NPSR1 Q6W5P4 2/20 0.52
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
MITF O75030 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
PBRM1 Q86U86 1/20 0.47
ADAM17 P78536 1/20 0.46
SLC22A6 Q4U2R8 1/20 0.44
MAPT P10636 3/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 2/20 0.43
APAF1 O14727 1/20 0.43
POLB P06746 1/20 0.43
RECQL P46063 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27474102 0.85 LMNA (0.58) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL10991862 0.83 ALDH1A1 (0.65) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL27462408 0.82 ALDH1A1 (0.52) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL4224310 0.82 ALDH1A1 (0.47) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL10981584 0.81 ALDH1A1 (0.44) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL10980705 0.79 ALDH1A1 (0.53) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL6394938 0.79 ALDH1A1 (0.56) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL5998914 0.78 LMNA (0.45) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL7970007 0.75 LMNA (0.57) LMNANPSR1ALDH1A1MEN1KMT2A
SCHEMBL10339734 0.75 MC1R (0.49) LMNANPSR1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009018368-A1 COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2009-02-05 WO claimed
EP-1009345-A4 SKIN AGING AND WOUND TREATMENT USING CELL MIGRATION AGENTS TIME BLOCK INC (US) 2002-03-13 EP claimed
EP-1009345-A1 SKIN AGING AND WOUND TREATMENT USING CELL MIGRATION AGENTS Time Block, Inc. (US) 2000-06-21 EP claimed
WO-1999000079-A1 SKIN AGING AND WOUND TREATMENT USING CELL MIGRATION AGENTS TIME BLOCK, INC. (US) 1999-01-07 WO claimed
US-11529342-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2022-12-20 US disclosed
CN-114088855-A Feces biomarker for early diagnosis of tibial cartilage dysplasia of broiler chicken and application thereof 河南农业大学 2022-02-25 CN disclosed
EP-3006023-B1 SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) 2019-06-26 EP disclosed
US-20190151301-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2019-05-23 US disclosed
EP-3006024-B1 BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) 2019-03-20 EP disclosed
US-10149845-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2018-12-11 US disclosed
US-10039730-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2018-08-07 US disclosed
US-20170189358-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2017-07-06 US disclosed
WO-2003047558-A2 TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE INHIBITORS GENSET S.A. (FR) 2003-06-12 WO disclosed
WO-2002066672-A2 TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS GENSET S.A. (FR) 2002-08-29 WO disclosed
US-20020053095-A1 METHODS FOR CONTROLLING GIBBERELLIN LEVELS ARNOLD WHITE & DURKEE 2002-05-02 US disclosed
EP-1009345-A4 SKIN AGING AND WOUND TREATMENT USING CELL MIGRATION AGENTS TIME BLOCK INC (US) 2002-03-13 EP disclosed
US-6174541-B1 Skin aging and wound treatment using cell migration agents HELEN OF TROY LIMITED (BB) 2001-01-16 US disclosed
EP-1009345-A1 SKIN AGING AND WOUND TREATMENT USING CELL MIGRATION AGENTS Time Block, Inc. (US) 2000-06-21 EP disclosed
WO-2000009722-A2 METHODS FOR CONTROLLING GIBBERELLIN LEVELS MONSANTO COMPANY (US) 2000-02-24 WO disclosed
WO-1999000079-A1 SKIN AGING AND WOUND TREATMENT USING CELL MIGRATION AGENTS TIME BLOCK, INC. (US) 1999-01-07 WO disclosed